Revvity/$RVTY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Revvity

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Ticker

$RVTY
Sector

Primary listing

NYSE

Employees

11,000

Revvity Metrics

BasicAdvanced
$11B
38.53
$2.37
0.95
$0.28
0.31%

What the Analysts think about Revvity

Analyst ratings (Buy, Hold, Sell) for Revvity stock.

Bulls say / Bears say

Revvity exceeded Q1 estimates with adjusted EPS of $1.01 versus $0.95 and revenue of $664.8 million versus $661.2 million, supported by consistent biotech demand, and raised its 2025 revenue guidance to $2.83 billion–$2.87 billion (Reuters).
For Q2 2025, Revvity reported adjusted EPS of $1.18, beating the $1.14 consensus, and revenue of $720.3 million, above the $710.4 million estimate, demonstrating strong operational performance (Barron’s).
More than half of Revvity’s revenue comes from international markets, and a weaker U.S. dollar gave a foreign exchange boost that helped justify its increased revenue outlook (Reuters).
Revvity’s Q2 adjusted operating margin fell to 26.6% from 28.8% year-over-year, indicating profitability is under pressure from higher costs (Barron’s).
The company lowered its full-year adjusted EPS guidance to $4.85–$4.95 from the previous $4.90–$5.00, coming in below the analyst consensus of $4.93, pointing to potential earnings headwinds (Barron’s).
Revvity highlighted a “meaningful pullback” in its immunodiagnostics business in China after DRG-related reimbursement changes triggered a double-digit sales drop, which caused shares to fall nearly 10% (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

Revvity Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Revvity Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RVTY

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs